证券代码：002821 证券简称：凯莱英 凯莱英医药集团（天津）股份有限公司 投资者关系活动记录表 编号：2023-003 投资者关系活动 √ 特定对象调研 □分析师会议 类别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称及 通讯参会：海通证券、兴业证券、国盛证券、中信证券、高盛 人员姓名 证券、华泰证券、富国基金、招商基金、银华基金、中金公司、 中欧基金、华夏基金、博时基金、上银基金、建信养老基金、 华商基金、嘉实基金、博裕资本、野村证券、高毅资产、Morgan Stanley、Fidelity、3W Asset、Point72 等 100 余家机构共计 283 人。 时间 2023 年 5 月 4 日 15：00-16：00 地点 通讯方式召开 上市公司接待人 董事&首席财务官 张达先生 员姓名 高级副总裁&董事会秘书 徐向科先生 一、2023 年第一季度经营概述 2023 年第一季度，公司实现营业总收入 22.49 亿元，同 比增长 9.09%；实现归母净利 6.30 亿元，同比增长 26.2%；经 调整净利润 7.01 亿元，同比增长 ...

1 2023第一季度 业绩说明会 凯莱英医药集团（天津）股份有限公司 2023年5月 凯莱英（股票代码：002821.SZ/6821.HK） 免责声明 本文件不得用于公开传播，其中所包含的信息仅供与凯莱英医药集团（天津）股份有限公司（"本公司"，连同其子公司，以下合称"本集团"）有关的人士及其顾问使用。 本公司仅向有限数量的收件人提供本文件。本文件的内容未经任何司法辖区的监管机构审阅。在某些司法辖区派发本文件可能会受到法律限制，持有本文件的任何人都应了 解并且遵守该等限制。任何不遵守该等限制的行为均可能违反美国、加拿大、中国或日本的证券法或其他类似司法辖区的法律。您一旦接收本文件，即代表您同意受到前述 限制的约束。 前瞻性陈述 本演示材料本演示材料有若干前瞻性陈述， 该等前瞻性陈述并非历史事实， 乃基于本公司的信念、 管理层所作出的假设以及现时所掌握的资料而对未来事件做出的预测。 尽管本公司相信所做的预测合理， 但是基于未来事件固有的不确定性， 前瞻性陈述最终或变得不正确。 前瞻性陈述受到以下相关风险的影响， 其中包括本公司所提供的服 务的有效竞争力、 能够符合扩展服务的时程表、 保障客户知识产权的能力、 行 ...

Financial Performance - The company achieved total revenue of CNY 2.25 billion in Q1 2023, representing a year-on-year increase of 9.09%[6] - Net profit attributable to shareholders reached CNY 630.35 million, up 26.22% compared to the same period last year[6] - The net profit excluding non-recurring items was CNY 617.64 million, reflecting a growth of 26.98% year-on-year[6] - Cash flow from operating activities surged to CNY 1.30 billion, a significant increase of 537.09% compared to the previous year[6] - The gross profit margin improved to 48.40%, an increase of 3.16 percentage points from the previous year, with gross profit amounting to CNY 1.09 billion[12] - Revenue from the small molecule CDMO business was CNY 2.00 billion, a year-on-year increase of 4.31%, with a 45.37% growth when excluding large orders[13] - Emerging business revenue reached CNY 249 million, marking a substantial growth of 72.54% year-on-year[14] - Total operating revenue for Q1 2023 reached ¥2,249,034,497.62, an increase of 9.1% compared to ¥2,061,708,856.14 in Q1 2022[24] - Operating profit for Q1 2023 was ¥709,948,636.92, up 24.5% from ¥570,097,662.75 in the same period last year[24] - Net profit attributable to shareholders for Q1 2023 was ¥630,346,004.43, compared to ¥499,398,084.81 in Q1 2022, reflecting a growth of 26.2%[25] - Basic and diluted earnings per share for Q1 2023 were both ¥1.72, an increase from ¥1.36 in Q1 2022[25] Assets and Liabilities - The total assets at the end of the reporting period were CNY 18.55 billion, a 1.69% increase from the end of the previous year[6] - Total current assets amount to ¥11,977,491,343.33, an increase from ¥11,860,458,372.35 at the beginning of the year[21] - Total liabilities decreased to ¥2,176,785,958.74 in Q1 2023 from ¥2,544,270,867.15 in Q1 2022, a reduction of approximately 14.5%[24] - Total equity attributable to shareholders increased to ¥16,324,854,569.41 in Q1 2023, up from ¥15,647,427,643.90 in Q1 2022, representing an increase of 4.3%[24] - The total liabilities and equity combined amounted to ¥18,546,760,048.14 in Q1 2023, compared to ¥18,239,273,651.93 in Q1 2022[24] Cash Flow - The cash inflow from operating activities for Q1 2023 was CNY 2,861,189,791.85, an increase of 48.8% compared to CNY 1,925,864,058.95 in Q1 2022[28] - The net cash flow from operating activities reached CNY 1,303,525,263.66, significantly up from CNY 204,607,061.83 in the same period last year[28] - Cash inflow from investment activities totaled CNY 8,399,828,818.08, compared to CNY 611,137,118.87 in Q1 2022, marking a substantial increase[28] - The net cash outflow from investment activities was CNY 327,218,213.85, an improvement from a net outflow of CNY 1,131,790,662.67 in Q1 2022[28] - The cash flow from financing activities showed a net inflow of CNY 383,841,586.32, with cash outflow for dividend payments recorded at CNY 3,889,772.50[29] - The total cash and cash equivalents at the end of Q1 2023 amounted to CNY 5,379,198,112.41, down from CNY 5,642,739,406.29 at the end of Q1 2022[29] - The company reported a cash inflow from the recovery of investments of CNY 8,368,856,153.32, a significant increase from CNY 607,807,000.00 in the previous year[28] - The cash outflow for purchasing goods and services was CNY 638,798,212.57, a decrease from CNY 1,003,677,026.11 in Q1 2022[28] - The total cash inflow from operating activities was CNY 2,861,189,791.85, while total cash outflow was CNY 1,557,664,528.19, resulting in a net cash flow of CNY 1,303,525,263.66[28] Shareholder Information - Total number of common shareholders at the end of the reporting period is 73,675[16] - ASYMCHEM LABORATORIES, INCORPORATED holds 31.12% of shares, totaling 115,133,168 shares[16] - HAO HONG holds 3.86% of shares, totaling 14,268,699 shares[16] - The company repurchased a total of 5,229,266 shares, accounting for 1.4134% of the total A+H share capital[18] - The company has not completed the transfer procedures for the employee stock ownership plan as of the end of the reporting period[19] Research and Development - Research and development expenses for Q1 2023 were ¥162,096,744.48, compared to ¥130,883,695.56 in Q1 2022, indicating a rise of 23.8%[24] - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[23] Market Expansion - The company plans to expand its market presence in Europe and Japan while focusing on cost control and efficiency improvements[12]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致之任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821) 2023年第一季度報告 本公告乃由凱萊英醫藥集團（天津）股份有限公司（「公司」或「本公司」，連同其 附屬公司「本集團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第 13.09條及第13.10B條以及證券及期貨條例（香港法例第571章）第XIVA部項下的 內幕消息條文（定義見上市規則）而作出。 以下為本公司的2023年第一季度報告。本季度報告所載之財務數據根據中國企業 會計準則編製。本2023年第一季度報告未經審計。 本公司2023年第一季度報告以中、英文雙語編製。如兩個版本有任何不相符之 處，應以中文版本為準。 承董事會命 凱萊英醫藥集團（天津）股份有限公司 Hao Hong博士 ...

Financial Performance - In 2022, Asymchem Laboratories achieved revenue of approximately RMB 10,230,186 thousand, an increase of 120.9% compared to RMB 4,632,121 thousand in the previous year[8]. - Gross profit for the year was approximately RMB 4,832,588 thousand, up 135.8% from RMB 2,049,725 thousand in 2021[8]. - Net profit attributable to shareholders was approximately RMB 3,301,635 thousand, representing a 208.8% increase from RMB 1,069,274 thousand in the prior year[8]. - Adjusted net profit attributable to shareholders, excluding IFRS adjustments, was approximately RMB 2,998,806 thousand, a 167.0% increase from RMB 1,122,997 thousand in 2021[8]. - Revenue increased significantly from RMB 1,822,787 thousand in 2018 to RMB 10,230,186 thousand in 2022, representing a compound annual growth rate (CAGR) of approximately 46.5%[9]. - Net profit attributable to shareholders rose from RMB 428,202 thousand in 2018 to RMB 3,301,635 thousand in 2022, reflecting a CAGR of about 56.5%[9]. - Gross profit margin improved from 46.0% in 2018 to 47.2% in 2022, indicating enhanced operational efficiency[9]. - The total assets increased from RMB 3,188,076 thousand in 2018 to RMB 18,239,273 thousand in 2022, showcasing robust growth in the company's asset base[9]. - The company achieved total revenue of RMB 10.23 billion in 2022, representing a year-on-year growth of 120.9%[31]. - The small molecule CDMO business generated revenue of RMB 9.23 billion, up 118.1% year-on-year, while emerging services revenue reached RMB 993 million, growing by 150.3%[31]. - Revenue from overseas markets amounted to RMB 8.67 billion, reflecting a year-on-year increase of 117.2%, with the Americas growing by 112.7% and the Asia-Pacific region (excluding China) increasing by 169.9%[35]. - The company's net profit attributable to shareholders reached RMB 3.30 billion, a significant increase of 208.8%, with a net profit margin of 32.3%[36]. - The gross profit margin improved to 47.2%, up 3.0 percentage points from 2021, driven by economies of scale and high capacity utilization[36]. Business Growth and Strategy - The company reported a significant growth in emerging business revenue, reaching nearly RMB 1 billion in 2022, a year-on-year increase of about 150%[6]. - Asymchem's strategic planning continues to evolve, focusing on technology-driven growth and exploring new business models to enhance revenue contributions[7]. - The company aims to maintain its leading position in small molecule CDMO while injecting new growth engines through emerging business developments[7]. - The company has achieved over 33% application rate of continuous reaction technology and biocatalysis technology in late-stage clinical projects[15]. - The company has expanded its small molecule CDMO service capabilities to include new drug categories such as peptides, oligonucleotides, monoclonal antibodies (mAb), antibody-drug conjugates (ADC), and mRNA[20]. - The company has established a comprehensive biocatalysis technology platform with over 2,400 enzymes in its library, 40% of which are proprietary intellectual property[21]. - The company’s fermentation production capacity reaches 10,000L per week, providing high-quality production capabilities from milligrams to tons[21]. - The company has provided process development and production services to over 800 global clients since 2016, including several blockbuster drugs with sales exceeding $1 billion[23]. - The company has established strong partnerships with 15 of the top 20 global pharmaceutical companies, maintaining long-term collaborations with eight of them for over ten years[28]. - The company is expanding its CDMO capabilities into new business areas such as peptides, oligonucleotides, and biologics, enhancing its service offerings[25]. Research and Development - The company invested RMB 708.9 million in R&D, marking an 83.0% increase and accounting for 6.9% of total revenue[68]. - The company has a workforce of over 4,656 scientists and engineers, supporting its advanced R&D platform and driving technological innovation[26]. - The company has achieved a 100% pass rate in 35 official audits by major regulatory agencies since 2011, including FDA and NMPA[27]. - The company has developed a comprehensive operational system that meets the highest global industry standards in R&D, production, quality control, and project management[27]. - The company is committed to enhancing its strategic decision-making through expert advisory committees, including the BSA and BDSA, to drive technological advancement and market expansion[30]. Market Trends and Projections - The global pharmaceutical R&D investment is projected to grow from USD 243.7 billion in 2022 to USD 328.8 billion by 2026, with a CAGR of approximately 7.8%[10]. - The outsourcing ratio of pharmaceutical R&D investment in China is expected to rise from 42.6% in 2022 to 52.2% by 2026, indicating a growing trend in outsourcing services[11]. - The number of pharmaceutical R&D companies in China surged by 43.3% from 522 in 2021 to 792 in 2022, reflecting a shift towards innovation[12]. - The global CDMO market for pharmaceutical R&D services is anticipated to grow from RMB 131.2 billion in 2022 to RMB 336.8 billion by 2026, with a CAGR of approximately 26.6%[13]. Corporate Governance and Leadership - The board consists of nine members, including four executive directors, two non-executive directors, and three independent non-executive directors[115]. - The company has a strong leadership team with extensive experience in various sectors, enhancing its strategic direction and operational efficiency[116][117][118][119][120]. - The board's composition reflects a balance of executive and independent oversight, ensuring robust governance practices[115]. - The company emphasizes the importance of good corporate governance for enhancing management and protecting overall shareholder interests[200]. - The board believes that the company has complied with the relevant provisions of the corporate governance code during the reporting period, except for clause C.2.1[200]. Sustainability and Compliance - The company is committed to sustainable development by creating low-energy, low-emission, and high-efficiency operational models[15]. - The company emphasizes the importance of environmental policies and has implemented measures to reduce energy consumption and waste[146]. - The company is committed to compliance with environmental, social, and governance regulations, with details to be disclosed in future reports[146]. - The company has not identified any significant non-compliance issues with relevant laws and regulations[146]. Future Outlook - The company has outlined a positive future outlook, projecting a revenue growth of 10-15% for the upcoming fiscal year[123]. - The company aims to deepen relationships with large clients while actively expanding its presence in the European and Japanese markets, focusing on cost control and efficiency improvements in 2023[106]. - The company plans to enhance its small molecule CDMO business and accelerate the development of strategic emerging businesses, leveraging a robust operational management system[106]. - The company is committed to enhancing clinical research services, aiming to establish a strong industry reputation and increase the number of clinical research service orders[110].

证券代码：002821 证券简称：凯莱英 公告编号：2023-023 凯莱英医药集团（天津）股份有限公司 出席本次说明会的人员有：公司董事长、首席执行官HAO HONG，董事、首席 财务官张达，高级副总裁兼董事会秘书徐向科，独立董事王青松（具体参会人员 以实际出席为准）。 为充分尊重投资者、提升交流的针对性，现就公司2022年度业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于2023年4月 20日（星期四）15：00前访问 https://ir.p5w.net/zj/，或扫描下方二维码， 进入问题征集专题页面。在信息披露允许的范围内，公司将在本次说明会上对投 资者普遍关注的问题进行回答。 欢迎广大投资者积极参与本次网上业绩说明会。 特此公告。 关于举办 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 凯莱英医药集团（天津）股份有限公司（以下简称"公司"）于2023年3月31 日 披 露 了 2022 年 年 度 报 告 全 文 及 摘 要 ， 相 关 内 容 详 见 巨 潮 资 讯 网 （http ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或倚賴該 等內容而引致的任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821） 截至2022年12月31日止年度之年度業績公告 凱萊英醫藥集團（天津）股份有限公司（「本公司」、「公司」、「凱萊英」）董事（「董 事」）會（「董事會」）欣然公布本公司及其附屬公司（統稱「本集團」、「我們」）截至 2022年12月31日止年度（「報告期」）的經審計綜合年度業績，連同截至2021年12 月31日止年度（「同期」）之比較數字。本集團於報告期間的綜合財務報表已由審核 委員會審閱及由本公司核數師安永會計師事務所審核。除非本公告另有界定，否 則本公告所用詞彙與本公司日期為2021年11月30日的招股章程（「招股章程」）所 界定者具有相同涵義。 本公告所載若干金額及百分比數字已作四捨五入調整，或約整至小數點後一位或 兩位 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB in 2022, representing a year-over-year growth of 25%[8]. - The company's operating revenue for 2022 reached ¥10,255,325,392.82, representing a 121.08% increase compared to ¥4,638,834,177.53 in 2021[14]. - The net profit attributable to shareholders for 2022 was ¥3,301,635,019.64, a significant increase of 208.77% from ¥1,069,273,577.50 in the previous year[14]. - The basic earnings per share for 2022 was ¥9.02, an increase of 186.35% compared to ¥3.15 in 2021[14]. - The company has set a revenue guidance of 1.8 billion RMB for the next fiscal year, reflecting a growth target of 20%[8]. - The gross margin improved to 45%, up from 40% in the previous year, due to enhanced operational efficiencies[8]. - The company reported a total cash dividend of RMB 1,456,119,192.54, which includes RMB 656,437,642.20 in cash dividends and RMB 799,681,550.34 from other methods such as share repurchase[153]. Research and Development - The R&D investment for new products and technologies reached 200 million RMB, accounting for 13% of total revenue, indicating a strong focus on innovation[8]. - The number of new drug applications submitted to regulatory authorities increased by 30%, reflecting the company's commitment to innovation and development[7]. - The company aims to launch three new innovative drugs in the next fiscal year, with expected sales of over 500 million RMB[7]. - The company has established a world-class R&D platform with over 4,656 scientists and engineers, focusing on continuous production and enzyme engineering technologies, which are critical for maintaining its competitive edge in the CDMO industry[32]. - The company is focused on expanding its clinical research services and aims to enhance the synergy between clinical CRO services and CDMO services[106]. - The company is actively involved in the development of new pharmaceutical technologies and processes, leveraging over 20 years of experience in the industry[136]. Market Expansion and Strategy - The company plans to expand its market presence in Europe and North America, targeting a 15% increase in market share over the next three years[8]. - The company is targeting increased penetration in the Japanese market and aims to achieve greater breakthroughs in the European market through new technologies[102]. - The company aims to deepen relationships with large clients and expand its market presence in Europe and Japan while focusing on cost control and efficiency improvements in 2023[101]. - The company is committed to optimizing management methods to improve R&D efficiency and reduce production costs, with a focus on early project development[103]. - The company is exploring potential acquisitions to enhance its capabilities in biologics, with a budget of 300 million RMB allocated for this purpose[8]. Operational Efficiency - The company aims to reduce production costs and improve efficiency through continuous process optimization during the commercialization phase[25]. - The company has developed a comprehensive operational system that meets the highest global industry standards, ensuring efficient project management and quality control throughout the drug development lifecycle[33]. - The company has implemented a new operational strategy focused on sustainability, aiming to reduce production waste by 40% over the next three years[132]. - The company has established a competitive compensation system to attract and retain high-quality employees, which includes basic salary, performance bonuses, and other benefits[151]. Corporate Governance - The company maintains independence from its controlling shareholder, ensuring no interference in decision-making or operational activities[112]. - The company has a clear performance evaluation and incentive mechanism to enhance work motivation and achieve operational goals[114]. - The company strictly adheres to information disclosure regulations, ensuring timely and accurate communication with investors[114]. - The company has established a performance evaluation system for senior management, linking compensation to the achievement of annual performance targets[158]. Environmental Compliance - Kailaiying Pharmaceutical Group strictly adheres to various environmental protection laws and regulations, ensuring compliance in its production operations[165]. - The company has established comprehensive waste treatment facilities, ensuring stable operation in accordance with national and local standards[166]. - The company has implemented new technologies to monitor and control emissions more effectively[175]. - The company has achieved compliance with national environmental standards, significantly reducing emissions of pollutants such as VOCs and COD[180]. Talent Development - The company has established the "Kailaiying Learning Center" to enhance employee training and development, focusing on cultivating elite talents in the CDMO sector[152]. - The company has a dual career development pathway for employees, allowing for both management and technical career advancements[152]. - The company emphasizes a people-oriented approach to human resource management, establishing mechanisms for talent selection, evaluation, and incentives to enhance sustainable development capabilities[108]. Risk Management - The company faces several risks, including the potential withdrawal or large-scale recall of major innovative drugs, operational risks in clinical projects, and risks related to the lifecycle replacement of key innovative drugs[2]. - The company has not reported any significant changes in the feasibility of its projects[92]. - The company did not identify any major risks or issues during its self-inspection of corporate governance and internal controls[164].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或倚賴該 等內容而引致的任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821） 截至2022年12月31日止年度之年度業績公告 凱萊英醫藥集團（天津）股份有限公司（「本公司」、「公司」、「凱萊英」）董事（「董 事」）會（「董事會」）欣然公布本公司及其附屬公司（統稱「本集團」、「我們」）截至 2022年12月31日止年度（「報告期」）的經審計綜合年度業績，連同截至2021年12 月31日止年度（「同期」）之比較數字。本集團於報告期間的綜合財務報表已由審核 委員會審閱及由本公司核數師安永會計師事務所審核。除非本公告另有界定，否 則本公告所用詞彙與本公司日期為2021年11月30日的招股章程（「招股章程」）所 界定者具有相同涵義。 本公告所載若干金額及百分比數字已作四捨五入調整，或約整至小數點後一位或 兩位 ...